About the Authors

Laure-Anne Van Bellinghen

Affiliation CHESS, Ternat, Belgium

Genevieve Meier


Affiliation Health Economics, GlaxoSmithKline Vaccines, Wavre, Belgium

Ilse Van Vlaenderen

Affiliation CHESS, Ternat, Belgium

Competing Interests

Funding for this research was provided by GSK. Genevieve Meier is an employee of the GlaxoSmithKline group of companies and holds restricted shares in the GlaxoSmithKline group of companies. Laure-Anne Van Bellinghen and Ilse Van Vlaenderen are employed by CHESS. Ilse Van Vlaenderen's and Laure-Anne Van Bellinghen's institution received consulting fees from the GlaxoSmithKline group of companies for conducting the present study and have also received consultancy fees from the GlaxoSmithKline group of companies for other projects and for writing manuscript outlines related to these other projects. GSK has a quadrivalent influenza vaccine marketed in the UK; this study is a model of the outcomes that could be “expected” for any injectable quadrivalent influenza vaccine should it be used in the UK. As the effectiveness was measured using data from a meta-analysis of injectable influenza vaccines from published clinical studies regardless of manufacturer. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: GM LVB IVV. Performed the experiments: GM LVB IVV. Analyzed the data: GM LVB IVV. Contributed reagents/materials/analysis tools: GM LVB IVV. Wrote the paper: GM LVB IVV.